HIGHLIGHTS
- who: J. Tabernero from the Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA have published the research: MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal canceru2606, in the Journal: (JOURNAL) of 31/05/2017
- what: The main reasons for drug discontinuation in the experimental versus control arms, respectively, during maintenance at 2 years` follow-up (data cut-off 31 May 2019) were: disease progression (60.6% versus 58.8%); adverse events (AEs; 14.1% versus 12.2%); physician decision (8 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.